Nanexa: One Dose is Enough
Initiating Coverage
2020-04-14
07:20
Redeye initiates coverage of Nanexa, an early-stage drug delivery company able to enhance compounds already on the market. Our confidence in management’s ability to commercialise its technology platform underpins our positive stance, while the share’s undemanding valuation after a recent capital raise provides an attractive entry point.
JS
Jakob Svensson
Disclosures and disclaimers